Showing 2341-2350 of 5623 results for "".
- Efficacy of Notal Vision Home OCT Demonstrated by a Series of Scientific and Clinical Workhttps://modernod.com/news/efficacy-of-notal-vision-home-oct-demonstrated-by-a-series-of-scientific-and-clinical-work/2480942/Notal Vision reported that scientific and clinical publications and presentations demonstrate the feasibility and efficacy of their patient-operated, home-based optical coherence tomography (OCT) device. As part of a comprehensive remote monitoring service, which includes a monitoring center and
- Kuria Therapeutics and Scohia Pharma Announce Licensing Agreement for Ophthalmic and Dermal Rights to SCO-116, A Novel Nrf2 Activatorhttps://modernod.com/news/kuria-therapeutics-and-scohia-pharma-announce-licensing-agreement-for-ophthalmic-and-dermal-rights-to-sco-116-a-novel-nrf2-activator/2480933/Kuria Therapeutics and Japanese biotech company Scohia Pharma announced that the companies have entered into a licensing agreement under which Kuria may develop, manufacture, and commercialize worldwide the locally delivered formulations of SCO-116, one of Scohia's internally discov
- EssilorLuxottica Chairman Leonardo Del Vecchio Passes Away at Age 87https://modernod.com/news/essilorluxottica-chairman-leonardo-del-vecchio-passes-away-at-age-87/2480931/Italian fashion icon Leonardo Del Vecchio, chairman of EssilorLuxottica, passed away at the age of 87, the company announced Monday. "The company expresses its deepest condolences to the family and to the global employee community for this enormous loss. The Board will m
- EyePoint Pharmaceuticals and OcuMension Therapeutics Announce Approval of Uveitis Treatment Yutiq in Chinahttps://modernod.com/news/eyepoint-pharmaceuticals-and-ocumension-therapeutics-announce-approval-of-nda-by-chinas-nmpa-for-uveitis-treatment-yutiq/2480925/EyePoint Pharmaceuticals and OcuMension Therapeutics announced that China’s Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) has approved Yutiq (fluocinolone acetonide intravitreal implant) 0.18mg for the treatment of chr
- Ace Vision Group Appoints Elizabeth Yeu, MD, as Chief Strategic Advisorhttps://modernod.com/news/ace-vision-group-appoints-elizabeth-yeu-md-as-chief-strategic-advisor/2480922/Ace Vision Group announced that Elizabeth Yeu, MD, partner at Virginia Eye Consultants, has been appointed to the role of chief strategic advisor. In her new position, Dr. Yeu will manage AVG's clinical advancement strategy. As a surgeon, researcher, and educator, Dr.
- Reichert Celebrates 100-Year Anniversary of the First Phoroptor Refracting Instrument Modelhttps://modernod.com/news/reichert-celebrates-100-year-anniversary-of-the-first-phoroptor-refracting-instrument-model/2480918/Reichert Technologiea, a business unit of Ametek, celebrated the 100-year anniversary of the first Phoroptor Refracting Instrument model. Released in 1922, this instrument helped transform eye care with its revolutionary ability to provide practitioners a better, faster, and more effici
- Holland Foundation for Sight Restoration Appoints Kila Hanrahan Director of Developmenthttps://modernod.com/news/holland-foundation-for-sight-restoration-appoints-kila-hanrahan-director-of-development/2480875/Kila Hanrahan, who has more than a decade experience in fundraising initiatives, has joined the Holland Foundation for Sight Restoration as Director of Development. “We are very excited to have Kila joining the Holland Foundation as the first employee,” said Holland Fo
- Qlaris Bio Reports Phase 2 Clinical Trial Results Demonstrating Favorable Safety and Tolerability Profile and Positive Efficacy Signal for QLS-101https://modernod.com/news/qlaris-bio-reports-phase-2-clinical-trial-results-demonstrating-favorable-safety-and-tolerability-profile-and-positive-efficacy-signal-for-qls-101/2480871/Qlaris Bio announced results from QC-201, a first-in-human, phase 2 clinical trial of QLS-101, the company’s investigational therapy for lowering IOP in the treatment of glaucoma. Study findings demonstrated a favorable safety and tolerability profile for QLS-101, including no evi
- Tarsus Presents New Findings From Two Studies That Demonstrate the Impact of Demodex Blepharitis at the ARVO 2022 Annual Meetinghttps://modernod.com/news/tarsus-presents-new-findings-from-two-studies-that-demonstrate-the-impact-of-demodex-blepharitis-at-the-arvo-2022-annual-meeting/2480847/Tarsus Pharmaceuticals, Inc. presented data from its Atlas Continuation study on the negative impact Demodex blepharitis has on daily life and visual function among certain patient groups, as well as preliminary findings from the Pandora study on the coexisting bacterial burden for patients with
- Clearside Biomedical Poster Presentation at ARVO 2022 Annual Meeting Demonstrates Versatility of Suprachoroidal Delivery Technologyhttps://modernod.com/news/clearside-biomedical-poster-presentation-at-arvo-2022-annual-meeting-demonstrates-versatility-of-suprachoroidal-delivery-technology/2480845/Clearside Biomedical, Inc. announced that several poster presentations were delivered on Clearside’s proprietary suprachoroidal delivery platform, XIPERE®, and gene therapy delivery utilizing Clearside’s SCS Microinjector® at the Association for Research in Vision and Ophthalm